Session

Overview: Radiosensitivity studies identify more and more biological mechanisms involved in tumour radioresistance. In this context, new drugs and biotechnologies are currently being developed to overcome this tumour radioresistance and improve radiotherapy treatments. This session aims at presenting three emerging radiobiological modifiers derived from: 1- serine/glycine metabolism hyperactivation in lung cancer and drug inhibition strategies, 2- metal nanoparticle radiosensitization, clinical trials and combinatory approaches, and 3- CRISP-Cas9 bioengineering for biomarker, cancer therapy and treatment combinations strategies.